Search
Lymecycline
go.drugbank.com/drugs/DB00256ApprovedInvestigationalWithdrawnIt is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. … Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and [tetracycline].[A19429,L13880]
Synonyms: N-Lysinomethyltetracycline, (+)-N-(5-Amino-5-carboxypentylaminomethyl)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamidePyrazinamide
go.drugbank.com/drugs/DB00339ApprovedInvestigationalA pyrazine that is used therapeutically as an antitubercular agent.
Tovorafenib
go.drugbank.com/drugs/DB15266ApprovedInvestigational[L50587] BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation, and differentiation. … Tovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity.
Synonyms: 4-Pyrimidinecarboxamide, 6-amino-5-chloro-N-[(1R)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-, 6-amino-5-chloro-N-[1R)-1-[5-[[[5-hloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimdinecarboxamideElosulfase alfa
go.drugbank.com/drugs/DB09051ApprovedInvestigationalElosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. … Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™.
Synonyms: Recombinant human N-acetylgalactosamine-6-sulfatase, Recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS)Agalsidase alfa
go.drugbank.com/drugs/DB15874ApprovedInvestigational[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009. … While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.
Betibeglogene autotemcel
go.drugbank.com/drugs/DB16900ApprovedInvestigational[L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin. … [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia
Alitretinoin
go.drugbank.com/drugs/DB00523ApprovedIt is used in the treatment of psoriasis; acne vulgaris; and several other skin diseases. It has also been approved for use in promyelocytic leukemia (leukemia, promyelocytic, acute). … An important regulator of gene expression during growth and development, and in neoplasms.
Famciclovir
go.drugbank.com/drugs/DB00426ApprovedInvestigationalFamciclovir, marketed as Famvir by Novartis, is a guanine analogue used to treat herpes virus infections. It is most commonly used to treat herpes zoster (shingles). … Famciclovir is a prodrug of penciclovir with higher oral bioavailability.
Favipiravir
go.drugbank.com/drugs/DB12466ApprovedInvestigationalDiscovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. … [A191688,A191772,A191775] Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for
Apixaban
go.drugbank.com/drugs/DB06605ApprovedInvestigationalIt is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043]. … Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic